menu
    • menu
    [{"orgOrder":0,"company":"Nanjing King-friend Biochemical Pharmaceutical","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Insulin aspart","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Nanjing King-friend Biochemical Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Nanjing King-friend Biochemical Pharmaceutical","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lefamulin Acetate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nanjing King-friend Biochemical Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Nanjing King-friend Biochemical Pharmaceutical \/ Meitheal Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Nanjing King-friend Biochemical Pharmaceutical

    Menu

    Nanjing King-friend Biochemical Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Nanjing King-friend Biochemical Pharmaceutical

    China arrow
    BePharma
    Not Confirmed

    Nanjing King-friend Biochemical Pharmaceutical

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lefamulin Acetate

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved

    Sponsor : Meitheal Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Meitheal Secures Licensing for XENLETA® to Expand Biopharmaceutical Portfolio

    Details : Meitheal secured commercial rights in the U.S. to Xenleta (lefamulin acetate) through an exclusive license agreement with its parent company. It is indicated for the CABP in adults.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    December 11, 2024

    Lead Product(s) : Lefamulin Acetate

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved

    Sponsor : Meitheal Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Nanjing King-friend Biochemical Pharmaceutical

    China arrow
    BePharma
    Not Confirmed

    Nanjing King-friend Biochemical Pharmaceutical

    China arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Insulin aspart

    Therapeutic Area : Endocrinology

    Study Phase : Preclinical

    Sponsor : Meitheal Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.

    Details : Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA.

    Product Name : Undisclosed

    Product Type : Peptide

    Upfront Cash : Undisclosed

    September 21, 2023

    Lead Product(s) : Insulin aspart

    Therapeutic Area : Endocrinology

    Highest Development Status : Preclinical

    Sponsor : Meitheal Pharmaceuticals

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth